MECP2 and myasthenia gravis: In this study, we employed specific antibodies targeting epigenetic marks associated with a transcriptional-permissive, unmethylated DNA (5-hydroxymethylcytosine, H3K4me3) or a transcriptional-restrictive, methylated DNA (5-methylcytosine, MeCP2) states, to evaluate epigenetic landscape alterations in murine MG cells in response to a well-documented MG dedifferentiation signal, N-methyl-D-aspartate (NMDA) (Karl et al., 2008; Ramírez and Lamas, 2009; Takeda et al., 2008; Reyes-Aguirre et al., 2013; Xiao et al., 2017; Carapia et al., 2023).